1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,480 | 1,740 | 22:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | IKONISYS: Number of shares and voting rights of Ikonisys SA as of December 23, 2025 | 1 | Euronext | ||
| 19.12.25 | Aliko Scientific raises €2.72 million through private placement and debt conversion | 1 | Investing.com | ||
| IKONISYS Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | Ikonisys SA: Ikonisys finalized a Capital Increase and Debt Conversion of EUR 2.72 million with strategic investment from Avantgarde Srl and Alberto Previtali | 363 | Business Wire | Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis... ► Artikel lesen | |
| 04.12.25 | Ikonisys SA: Ikonisys: Cytofast Auto: The First Fully Automatic Universal Monolayer Cytology Processor Is Born | 286 | Business Wire | Regulatory News:
Hospitex international, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices... ► Artikel lesen | |
| 24.11.25 | Ikonisys SA: Ikonisys: Hospitex Initiates International Dialogues for Pilot Projects in Oncology Diagnostics Following ADB Delegation Visit | 406 | Business Wire | Regulatory News:
Hospitex, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, announces... ► Artikel lesen | |
| 07.10.25 | Ikonisys SA: Hospitex Wins Public Tender at Policlinico di Bari for Cytofast Cytology Systems | 259 | Business Wire | Regulatory News:
Hospitex,the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, has been... ► Artikel lesen | |
| 30.09.25 | XFRA 9W8: WIEDERAUFNAHME/RESUMPTION | 155 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 01.07.25 | Ikonisys SA: Suspension of Trading of Shares on Euronext Growth Paris Until the Publication of the 2024 Annual Report | 346 | Business Wire | Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis... ► Artikel lesen | |
| 01.07.25 | XFRA 9W8: AUSSETZUNG/SUSPENSION | 348 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILIKONISYS EO 2 9W8... ► Artikel lesen | |
| 04.06.25 | ALIKO SCIENTIFIC (Ikonisys SA), Through Its Fully Owned Italian Subsidiary Hospitex International, Signs Exclusive Distribution Agreement for Italy with Menarini Diagnostics | 350 | Business Wire | Regulatory News:
ALIKO SCIENTIFIC (Ikonisys SA) Euronext Growth: ALIKO, through its fully owned Italian subsidiary Hospitex International is pleased to announce the signing of an exclusive distribution... ► Artikel lesen | |
| 30.05.25 | Ikonisys SA: Ikonisys Announces a Further Postponement of the Publication of Its 2024 Annual Financial Report | 375 | Business Wire | Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis... ► Artikel lesen | |
| 02.05.25 | Ikonisys SA: Ikonisys Finalized a Capital Increase Through the Offsetting of Debt | 384 | Business Wire | Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis... ► Artikel lesen | |
| 25.04.25 | Ikonisys Announces the Postponement of the Publication of Its 2024 Annual Financial Report | 337 | Business Wire | Regulatory News:
ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution... ► Artikel lesen | |
| 03.04.25 | Ikonisys SA: Hospitex International Launches Urine24, the First-Online Urinary Cytology Test Platform, Marking a Breakthrough in Early Bladder Cancer Diagnosis in Italy | 400 | Business Wire | Regulatory News:
ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), announces that its Italian subsidiary Hospitex International has launched Urine24.com, the first online-available... ► Artikel lesen | |
| 10.03.25 | Ikonisys SA Wins Public Tender with F. Miulli Regional General Hospital for Pathological Anatomy | 349 | Business Wire | Regulatory News:
Hospitex, the Italian leader in the production of Cytology medical devices and fully owned subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), a company... ► Artikel lesen | |
| 27.02.25 | Ikonisys SA: Ikonisys Finalized a Capital Increase Through a Private Placement | 621 | Business Wire | Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 42,600 | -0,47 % | Aktie leicht im Minus: Siemens Healthineers enttäuscht mit schwachem Start ins neue Geschäftsjahr | © Foto: Daniel Karmann/dpa Siemens Healthineers startet schwächer ins neue Geschäftsjahr. Während das Kerngeschäft wächst, belasten Währungseffekte und die schwierige Lage in China die Ergebnisse. Dennoch... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,480 | +0,52 % | Fresenius Medical Care: Ein genauer Blick in Richtung USA | Der Markt rechnet 2025 bei Fresenius Medical Care (FMC) mit einem Umsatz von 19,6 Millairden Euro und einem EBIT von rund 1,8 Milliarden Euro. Im Modell der Analysten von mwb research stehen 19,7 Milliarden... ► Artikel lesen | |
| FRESENIUS | 49,240 | -0,32 % | Fresenius - FRE: Dax-Konzern mit Breakout-Setup! | Swingtrade JETZT? Analysten erwarten für Fresenius (FRE) weiteres Wachstum in 2026, geben Kaufempfehlungen und nennen als Kursziel 57 EUR! Fresenius (FRE) - ISIN DE0005785604 Rückblick: Ein Aufwärtstrend... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 38,360 | +2,87 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| HEARTFLOW | 25,970 | -7,58 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 27,340 | -1,23 % | Brenntag, Carl Zeiss Meditec, Evonik, Hypoport, Porsche, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 27,400 | -5,32 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,150 | -0,80 % | Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026 | Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year... ► Artikel lesen | |
| GENEDX | 84,08 | -1,37 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PROGYNY | 21,920 | -3,86 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| GERRESHEIMER | 25,160 | +0,08 % | Gerresheimer, HelloFresh, Hensoldt, Renk, TeamViewer, TUI, Zalando: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| UNITEDHEALTH | 227,85 | -2,48 % | Zahlenflut und Fed Sitzung! Intel, UnitedHealth, Oklo, Starbucks, Meta, Microsoft, Tesla im Check | Der Fed-Zinsentscheid ist durch - und wie erwartet bleibt alles beim Alten. Wir ordnen die Aussagen von Jerome Powell ein und erklären, warum Zinssenkungen vorerst kein Thema sind. Außerdem im Fokus:... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,500 | -2,32 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,945 | -3,51 % | Frontalangriff: Hatte Novo das auf der Rechnung? Hims kontert mit billiger Pillen-Variante! | © Foto: DALL-EWährend die Aktien von Hims mit einem zweistelligen Plus in den Handelstag startet, muss Novo Nordisk erneut kräftig Federn lassen. Die US-Pharmaplattform startet den Verkauf einer deutlich... ► Artikel lesen | |
| CLEARPOINT NEURO | 12,570 | -5,56 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen |
Das Unternehmen IKONISYS kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,65 % bei einem Aktienkurs von 1,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IKONISYS finden Sie auf Wallstreet Online.